论文部分内容阅读
目的:探讨布地奈德福莫特罗吸入治疗对慢性支气管哮喘患者的临床疗效及其对患者血清炎性因子水平、肺功能和生活质量的影响。方法:选择2014年2月至2016年2月于我院呼吸内科就诊并确诊为慢性支气管哮喘患者123例,根据随机数字表法分为观察组65例和对照组58例。比较两组患者治疗前后血清白介素17(IL-17)、白介素33(IL-33)、基质金属蛋白酶9(MMP-9)、肺功能、生活质量评分的变化、临床疗效有效率及不良反应的发生情况。结果:观察组的总有效率为92.3%(60/65),显著高于对照组(81.03%,P<0.05)。治疗后,两组患者的血清IL-17、IL-33水平与治疗前相比均显著降低(P<0.05),且观察组显著低于对照组(P<0.05);两组血清MMP-9水平与治疗前相比差异均无统计学意义(P>0.05);观察组患者的第一秒用力呼吸容积(FEV1)、峰值呼气流速(PEF)与第一秒用力呼气容积与用力肺活量比值(FEV1/FVC)水平均明显增加,且观察组上述指标明显高于对照组(P<0.05);圣.乔治呼吸问卷(SGRQ)评分结果显示观察组患者的生活质量显著高于对照组患者。结论:布地奈德福莫特罗吸入治疗对慢性支气管哮喘临床效果显著,可显著控制炎症反应,改善肺功能,显著提升患者生活质量。
Objective: To investigate the clinical efficacy of inhaled budesonide formoterol for patients with chronic bronchial asthma and its effect on serum inflammatory factors, lung function and quality of life. Methods: A total of 123 patients with chronic bronchial asthma who were diagnosed as chronic bronchial asthma in our hospital from February 2014 to February 2016 were selected and divided into observation group (n = 65) and control group (n = 58) according to random number table. The changes of serum IL-17, IL-33, MMP-9, pulmonary function and quality of life before and after treatment were compared between the two groups. The clinical efficacy and adverse reactions What happened? Results: The total effective rate in the observation group was 92.3% (60/65), significantly higher than that in the control group (81.03%, P <0.05). After treatment, the serum levels of IL-17 and IL-33 in both groups were significantly lower than those before treatment (P <0.05), and the levels in the observation group were significantly lower than those in the control group (P <0.05) (P> 0.05). The first second forced expiratory volume (FEV1), peak expiratory flow (PEF) and first expiratory volume and forced vital capacity in the observation group were significantly higher than those in the control group (FEV1 / FVC) were significantly increased, and the above indicators in the observation group were significantly higher than those in the control group (P <0.05). The SGRQ score showed that the quality of life of the observation group was significantly higher than that of the control group . Conclusion: The inhaled budesonide formoterol has a significant clinical effect on chronic bronchial asthma, which can significantly control the inflammatory response, improve lung function and significantly improve the quality of life of patients.